Publication | Open Access
ADXS11-001 immunotherapy targeting HPV-E7: final results from a Phase II study in Indian women with recurrent cervical cancer
21
Citations
0
References
2014
Year
Microbial PathogensImmunologyImmunodominanceAntigen ProcessingImmunotherapeuticsImmune SystemImmunotherapySynthetic ImmunologyCervical Cancer PreventionCancer-associated VirusHuman Papillomavirus VaccinesPublic HealthFinal ResultsRadiation OncologyAbstracts Adxs11-001 ImmunotherapyAdxs11-001 ImmunotherapyCervical HealthMedicineLm VectorVirologyT Cell ImmunityCervical Cancer ManagementCervical CancerPathogenesisRecurrent Cervical CancerMicrobiologyVaccine DesignOncologyViral OncologyViral ImmunityTllo-hpv-16-e7 FusionPrecancerous Lesions
Meeting abstracts ADXS11-001 immunotherapy is a live attenuated Listeria monocytogenes ( Lm ) bioengineered to secrete a tLLO-HPV-16-E7 fusion protein targeting HPV-transformed cells. The Lm vector serves as its own adjuvant and infects APC where it cross presents HPV-E7-tLLO fusion peptide,